Medifast initiated with an Equal Weight at Stephens

Stephens initiated coverage of Medifast with an Equal Weight rating and $82 price target. Medifast has a “unique approach to weight management” and asset light model, which means Medifast can deliver “impressive” cash flow generation and operating leverage when sales are growing, the analyst tells investors. However, the current economic backdrop presents a “challenging environment for Medifast,” the analyst added.